Suchergebnisse - "Rautenberg, T."

PubPharm (15)

1

Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models

enthalten in: Journal of medical economics | 2020

von Rautenberg, T. | George, G. | Bwana, M. | +13

2

Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women : a Phase 1 randomized controlled trial

enthalten in: Human reproduction (Oxford, England) | 2016

von Schultze-Mosgau, M. | Waellnitz, K. | Nave, R. | +5

3

A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women

enthalten in: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | 2016

von Waellnitz, K. | Duijkers, I. | Klipping, C. | +3

ErratumIn: J Obstet Gynaecol. 2016;36(1):i. - PMID 26790820

4

Methods to construct a step-by-step beginner’s guide to decision analytic cost-effectiveness modeling

in: ClinicoEconomics and Outcomes Research | 2016

von Rautenberg T | Hulme C | Edlin R

5

A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women

enthalten in: Journal of obstetrics and gynaecology | 2016

von Rautenberg, T. | Rohde, B. | Klipping, C. | +3

6

Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial

enthalten in: Human reproduction | 2016

von Schultze-Mosgau, M. | Waellnitz, K. | Nave, R. | +5

7

Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial

enthalten in: Human reproduction | 2016

von Schultze-Mosgau, M. | Waellnitz, K. | Nave, R. | +5

8

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

enthalten in: Journal of medical economics | 2014

von Rautenberg, T. | Siebert, U. | Arnold, D. | +4

ErratumIn: J Med Econ. 2014 Mar;17(3):231

9

Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countries

enthalten in: Value in health | 2013

von Rautenberg, T. | Tournier, C. | Ngoh, C. | +11

10

PMD30 Short Term Health-Economic Outcomes of Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes: A Cost Comparison Analysis

enthalten in: Value in health | 2012

von Fortwaengler, K. | Rautenberg, T. | Caruso, A.